Ms. Hoult joined Fletcher Spaght, Inc. in 2009. She has over 20 years of biotechnology, life science and healthcare experience as a consultant and in marketing and business development roles for various biotechnology and diagnostics firms including ZymoGenetics, Blue Heron Biotechnology and NeoPath (which subsequently merged to form TriPath and was acquired by BD Diagnostics). Ms. Hoult earned a BA in Biology and Environmental Studies from Dartmouth College and an MBA from the Stanford Graduate School of Business.